Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    20625137 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
Conditions: Non Hodgkin's Lymphoma;   NHL;   Aggressive NHL;   Diffuse Large B-cell Lymphoma
Interventions: Drug: Veltuzumab and 90Y-Epratuzumab Tetraxetan;   Drug: 90Y-epratuzumab tetraxetan;   Drug: veltuzumab

Indicates status has not been verified in more than two years